About us

We partner with scientists and entrepreneurs to launch and build exceptional biotech companies

Our story

We have supported 13 ventures to date. Since supporting our first ventures in early 2018, eight of our portfolio companies have, in total, raised over $270 million in financing. Several collaborations have been initiated and one company has been sold. As of early 2020, we have added another four companies to our portfolio and have also been instrumental in contributing to the development of six more ventures in the Basel Area.

BaseLaunch was initiated to help launch and grow the next generation of biotech companies. To achieve this, we collaborate closely with key players from the biotech sector, leading pharmaceutical companies and venture funds. Our partners are Roche, BB Pureos Bioventures, Roivant Sciences, Bridge Bioventures, CSL Behring, Johnson & Johnson and China Medical System.

BaseLaunch is managed and operated by Basel Area Business & Innovation, the innovation and investment promotion agency for the Basel Area.

See our portfolio

Basel Area: A leading Life Sciences hub

The Basel Area is a biopharma hotspot. It is home to Roche and Novartis, two of the world’s largest pharmaceutical companies, as well as Actelion, now part of Johnson & Johnson, and formerly one of Europe’s most successful biotechs.

However, it is not just about big pharma. The Basel Area is a hotbed of innovation with numerous small to medium biotech companies, world class research institutions, marquee venture capitalists and several technology parks.

The tightly interwoven academic and biopharma environment feeds a tremendous flow of innovation in the Basel Area which is also reflected in the significant venture capital investments of over $2.5 billion that have been made in the last few years. This, together with the deep talent pool of the region, and the entrepreneur-friendly economic policies of Switzerland, makes the Basel Area the ideal breeding ground for new biopharma ventures.

BaseLaunch is deeply embedded within this ecosystem, while also being connected to the global biopharma community – and we utilize both networks for the benefit of the ventures we support.

Key facts

It offers 700+ life sciences companies
32’000+ employees
With close access to top biomedical research including $21B+ in research spending


With close access to top biomedical research including $21B+ in research spending; 1000+ research groups; 13+ research institutes.
1000+ research groups
$5B+ public and private financings raised last few years

Success stories

Some of our successes (click on the logo to learn more)

Read success stories